Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
Climb Bio presented initial Phase 1 safety data for CLYM116 at the European Renal Association Congress, showing a favorable profile with no unexpected safety findings in healthy volunteers. Translational pharmacometric modeling suggests CLYM116 could offer less frequent dosing than first-generation anti-APRIL therapies, driven by its novel 'sweeper' mechanism.
Key figures
- Drug Name
- CLYM116
- Phase Of Trial
- Phase 1
- Dose range mg
- 25 mg to 640 mg
- Max dose tested mg
- 320
- Global phase1 target n
- 80
- Healthy volunteer count
- 49
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.